Stocks · News reference
Sensirion has launched the SFM3304-D, a single-use gas flow sensor designed for proximal flow measurement in mechanical ventilation and respiratory applications.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Senseonics Holdings, Inc. has commenced the first-in-human clinical study for its investigational 'Freedom' continuous glucose monitoring (CGM) system, which is designed to operate without an external on-body transmitter.
Senseonics announced the initiation of its first-in-human clinical study for Freedom, an investigational next-generation continuous glucose monitoring (CGM) system designed to communicate directly with mobile devices without an external transmitter. Built on proven Eversense 365 technology and supported by encouraging preclinical data, Freedom aims for potential commercial launch in 2028, with a pivotal study expected to begin in 2027.
Senseonics management will participate in the Stifel 2026 Healthcare Conference and the 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum in November.